title: Pulmonary artery catheterization and clinical outcomes: National Heart, Lung, and Blood Institute and Food and Drug Administration Workshop Report. Consensus Statement.
abstract: OBJECTIVE
  The efficacy and safety of the pulmonary artery catheter are under scrutiny because of its association with increased morbidity and mortality in observational studies. In response, the National Heart, Lung, and Blood Institute (NHLBI) and the US Food and Drug Administration (FDA) conducted the Pulmonary Artery Catheterization and Clinical Outcomes workshop in Alexandria, Va, on August 25 and 26, 1997, to develop recommendations regarding actions to improve pulmonary artery catheter utility and safety.
  
  
  METHODS
  The NHLBI and FDA planning task force selected a workshop chairperson, subcommittee chairs, and participants. Approximately 85 participants were selected for their collective expertise in critical care, pulmonary medicine, cardiovascular medicine and surgery, pediatrics, nursing, biostatistics, and medical economics. The meeting was open to industry representatives and other government and lay observers. This workshop was funded by the NHLBI and the FDA's Division of Devices.
  
  
  METHODS
  Published reports relating to the efficacy and safety of the pulmonary artery catheter, especially consensus documents developed by professional societies.
  
  
  METHODS
  The planning task force disseminated materials, held teleconferences, and developed draft position papers prior to the workshop. These were modified during the workshop and thereafter in the course of several teleconferences, and presented to the entire group for final modifications and approval.
  
  
  CONCLUSIONS
  A need exists for collaborative education of physicians and nurses in performing, obtaining, and interpreting information from the use of pulmonary artery catheters. This effort should be led by professional societies, in collaboration with federal agencies, with the purpose of developing and disseminating standardized educational programs. Areas given high priority for clinical trials were pulmonary artery catheter use in persistent/refractory congestive heart failure, acute respiratory distress syndrome, severe sepsis and septic shock, and low-risk coronary artery bypass graft surgery. JAMA. 2000;283:2568-2572
authors.affiliation: Room T-1219 Medical Center North, Vanderbilt University School of Medicine, Nashville, TN 37232, USA. Gordon.Bernard@mcmail.vanderbilt.edu
authors.forename: G R
authors.initials: GR
authors.lastname: Bernard
authors.forename: G
authors.initials: G
authors.lastname: Sopko
authors.forename: F
authors.initials: F
authors.lastname: Cerra
authors.forename: R
authors.initials: R
authors.lastname: Demling
authors.forename: H
authors.initials: H
authors.lastname: Edmunds
authors.forename: S
authors.initials: S
authors.lastname: Kaplan
authors.forename: L
authors.initials: L
authors.lastname: Kessler
authors.forename: H
authors.initials: H
authors.lastname: Masur
authors.forename: P
authors.initials: P
authors.lastname: Parsons
authors.forename: D
authors.initials: D
authors.lastname: Shure
authors.forename: C
authors.initials: C
authors.lastname: Webb
authors.forename: H
authors.initials: H
authors.lastname: Weidemann
authors.forename: G
authors.initials: G
authors.lastname: Weinmann
authors.forename: D
authors.initials: D
authors.lastname: Williams
mesh_terms: D002407:Catheterization, Swan-Ganz; D003422:Critical Care / Q000592:standards; D006801:Humans; D017063:Outcome Assessment, Health Care; D018570:Risk Assessment